Figure 1. CBD related receptors and potential
therapeutic benefits. CBD acts as agonist of the receptors TRPV1,
PPARγ, and 5-HT1A, and as antagonist of the receptor
GPR55. CBD is an inverse agonist of the receptors GPR3, GPR5, and GPR12.
Moreover, CBD antagonizes the action of CB1 and CB2 receptors agonists,
and is suggested to act as an inverse agonist and a negative allosteric
modulator of these receptors. CBD also inhibits FAAH, which results in
increased anandamide levels. Anandamide activates CB1, CB2, and TRPV1
receptors. Clinical studies revealed that CBD has potential therapeutic
benefits for psychotic disorders, anxiety, epilepsy, sleep,
cardiovascular related diseases, diabetes, pain management and cancer
treatment. 5-HT1A, serotonin receptor 1A; CB1,
cannabinoid receptor type 1; CB2, cannabinoid receptor type 2; FAAH,
fatty acid amide hydrolase; GPR3, G-protein-coupled receptor 3; GPR6,
G-protein-coupled receptor 6; GPR12, G-protein-coupled receptor 12;
GPR55, G-protein-coupled receptor 55; PPARγ, peroxisome
proliferator-activated receptor gamma; TRPV1, transient receptor
potential vanilloid type 1.